

Controversies on EAU Guidelines: Testicular and renal cancer and stones

Thematic Session

Monday 13 March
12:30 - 14:00

Location Yellow Area, eURO Auditorium 1

Chairs
B. Ljungberg,Umeå (SE)
D. Nicol,London (GB)
A. Skolarikos,Athens (GR)

Learning objectives

This session explores some of the less clearly-defined topics in the EAU Guidelines, where debate and controversy exist. The session will cover, in 30-minute debates, testicular cancer, renal cancer and stones. We are expecting your interactive participation!

The EAU Guidelines recommend retroperitoneal lymph node dissection (RPLND) for patients presenting with stage II marker negative disease. The issue is less clear for stage I patients undergoing surveillance who subsequently relapse with stage II disease. The case for initial surgery in this clinical scenario will be debated in this EAU Guidelines Controversy session. Opposing views will be presented by clinicians. A patient's perspective will also be presented as an additional consideration in considering the initial options of surgery or chemotherapy. A panel will then discuss.

The second debate considers the question of optimal treatment for patients with primary metastatic RCC cytoreductive nephrectomy after response to immune check point inhibitors. Experts will argue, followed by a panel discussion.

The EAU Guidelines algorithms for urinary stone treatment are mainly based on stone composition and stone size. This is largely due to the best evidence existing in the literature. Currently, the patient-reported outcomes on their quality of life during and after the applied "stone treatments" are not well documented. In the third debate, experts will discuss whether stone-free rates are more important than the quality of life.

12:30 - 13:03

Debate Surgery is the preferred option for stage IIA relapse of NSGCT

12:30 - 12:33

Introduction

D. Nicol,London (GB)

12:33 - 12:38

Yes

A. Heidenreich,Cologne (DE)

12:38 - 12:43

No

G. Daugaard,Copenhagen (DK)

12:43 - 12:48

Patient's view

R. Cornes,London (GB)

12:48 - 13:03

Discussion

Discussant R. Leão,Coimbra (PT)

Panel
R. Cornes,London (GB)
G. Daugaard,Copenhagen (DK)
A. Heidenreich,Cologne (DE)

13:03 - 13:31

Debate Should deferred cytoreductive nephrectomy be performed in primary metastatic RCC after response to immune check point inhibitors?

13:03 - 13:06

Introduction

B. Ljungberg,Umeå (SE)

13:06 - 13:11

Yes

T. Kuusk,London (GB)

13:11 - 13:16

No

P.J. Zondervan,Amsterdam (NL)

13:16 - 13:31

Discussion

Discussant J. Bedke,Tübingen (DE)

Panel T. Kuusk,London (GB)
P.J. Zondervan,Amsterdam (NL)

13:31 - 13:59

Debate Are stone-free rates more important than Quality of Life?

13:31 - 13:34

Introduction

A. Skolarikos,Athens (GR)

13:34 - 13:39

Yes

N. Davis,Dublin (IE)

13:39 - 13:44

No

R. Geraghty,Newcastle upon Tyne (GB)

13:44 - 13:59

Discussion

Discussant A. Petřík,Ceske Budejovice (CZ)

Panel N. Davis,Dublin (IE)
R. Geraghty,Newcastle upon Tyne (GB)

13:59 - 14:00

Closing remarks
